Experience

BioAgilytix

• United States
• Biotechnology Research
• 700 & Above Employee

• Director, Scientific Services

  • Jan 2023 - Present



BioAgilytix Boston (previously Cambridge Biomedical Inc.)

• Associate Director, Scientific Services

  • Oct 2019 - Dec 2022



STC Biologics Inc

• United States
• Biotechnology Research
• 1 - 100 Employee

• Director, Biology

  • 2012 - Oct 2019

  Cambridge, MA Establishing immunoassays for biosimilars and novel therapeutic candidates product pipeline. Responsible for day-to-day lab operations.



2008-2012

• Principal Scientist

  • 2008 - 2012

  Established Merrimack’s Tumor Immunology discovery-stage research program with colleagues. Project evolved from presentation of the project proposal at a company-wide “innovation forum”. Project was subsequently voted on for approval by Merrimack Executive Leadership. The goal was to drive tumor cells to provoke anti-tumor immunity using novel lipid nanoparticles. Developed a high-throughput FACs-based screening assay of ex vivo murine splenocytes to identify candidate immune… Show more Established Merrimack’s Tumor Immunology discovery-stage research program with colleagues. Project evolved from presentation of the project proposal at a company-wide “innovation forum”. Project was subsequently voted on for approval by Merrimack Executive Leadership. The goal was to drive tumor cells to provoke anti-tumor immunity using novel lipid nanoparticles. Developed a high-throughput FACs-based screening assay of ex vivo murine splenocytes to identify candidate immune activators resulting in a lead molecule. Led a group investigating the development of novel cell adhesion inhibitors for the treatment of auto-immune and inflammatory diseases. Oversaw multiple functionalities including cell biologists, protein chemists and modelers with the objective of understanding the biophysical characteristics and potency of our test molecules. Utilized design and production of protein-based therapeutics and research tools employed for testing therapeutic efficacy, including 3H-based proliferation assays, transfection and cell line development. Show less



Merrimack

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist

  • 2005 - 2008

  Supervised three direct reports investigating the mechanism of action (MOA) of MM-093 recombinant human alpha fetal protein (AFP). Implemented multiple orthogonal techniques including multi-parameter flow cytometry, BrDU apoptosis assays and proliferation assays to assess MM-093. Designed, executed and oversaw in vivo analysis of MM-093 in animal models of auto-immune and inflammatory disease (EAE and collagen-induced arthritis). Managed data flow from two Phase II… Show more Supervised three direct reports investigating the mechanism of action (MOA) of MM-093 recombinant human alpha fetal protein (AFP). Implemented multiple orthogonal techniques including multi-parameter flow cytometry, BrDU apoptosis assays and proliferation assays to assess MM-093. Designed, executed and oversaw in vivo analysis of MM-093 in animal models of auto-immune and inflammatory disease (EAE and collagen-induced arthritis). Managed data flow from two Phase II clinical trials of MM-093 (120 patients; RA and Uveitis) which included interaction with our clinical teams, as well as with multiple CROs. Identified in-house resources to implement MatLab software for the analysis of high-content data sets. Promoted to Principal Scientist for leadership of these efforts. Show less



Center for Blood Research

• Postdoctoral Fellow

  • Jan 1999 - Jan 2005

  Obtained NIH post-doctoral funding to execute on two main projects: 1. Generated knock-in mice expressing a mutant complement receptor Validated hypothesis that mice expressing B cells that could bind and retain complement-tagged antigen but not initiate signaling would be defective in the maintenance of B cell memory we developed knock-in mice expressing mutant complement receptor in which the transmembrane and signaling domains of complement receptors 1/2 (CD21/CD35) were replaced… Show more Obtained NIH post-doctoral funding to execute on two main projects: 1. Generated knock-in mice expressing a mutant complement receptor Validated hypothesis that mice expressing B cells that could bind and retain complement-tagged antigen but not initiate signaling would be defective in the maintenance of B cell memory we developed knock-in mice expressing mutant complement receptor in which the transmembrane and signaling domains of complement receptors 1/2 (CD21/CD35) were replaced with signaling-incompetent regions of the human HLA molecule. Performed all phases of construct generation, ES cell clone selection, animal breeding and subsequent immunologic studies. 2. Demonstrated Receptor editing in developing B cells Elucidated tolerigenic mechanisms operative during development of transgenic (HEL; Hen Egg Lysozyme) B cell progenitors. Learned embryonic fetal liver organ culture, multi-color FACs staining, sorting and single cell RT-PCR/sequencing of Heavy and Light chain genes. Show less



Boston University

• United States
• Higher Education
• 700 & Above Employee

• PhD student

  • 1993 - 1999

  Cloned a novel gene, faim, which confers resistance to Fas-mediated apoptosis. Taught myself differential display (a technique to clone genes) for this project. Published faim paper in the Journal of Experimental Medicine. Spoke at Keystone Symposium to describe this work. Awarded patent as a result of this work. KEY SKILLS Motivated learner of new software, techniques, approaches. Management and oversight of full time employees. Recognized Expert and resource… Show more Cloned a novel gene, faim, which confers resistance to Fas-mediated apoptosis. Taught myself differential display (a technique to clone genes) for this project. Published faim paper in the Journal of Experimental Medicine. Spoke at Keystone Symposium to describe this work. Awarded patent as a result of this work. KEY SKILLS Motivated learner of new software, techniques, approaches. Management and oversight of full time employees. Recognized Expert and resource for FACs/cell sorting (certified FACs Aria operator, adept with Coulter iEpics/Elite instruments). Design, execution and oversight of in vivo animal models of auto-immune and inflammatory disease- EAE, NOD, and Arthritis. Translational research: immunologic cell-based assays of ex vivo clinical samples. Clinical trial design, oversight, and guidance of CROs. All aspects of gene cloning, protein expression and purification. Data analysis employing multiple formats including MatLab, GraphPad Prizm and Excel. Show less